Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice

References

• CrismonMLKatturaRSBuckleyPFSchizophreniaDiPiroJTTalbertRLYeeGCPharmacotherapy: A Pathophysiologic Approach, 10eNew York, NYMcGraw-Hill Education2017
   Google Scholar
• APADiagnostic and Statistical Manual of Mental Disorders5th edWashington, DCAmerican Psychiatric Association2013
   Google Scholar
• BuchananRWKreyenbuhlJKellyDLSchizophrenia Patient Outcomes Research Team (PORT)The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2010361719319955390
   PubMed Web of Science ®Google Scholar
• OsserDNRoudsariMJManschreckTThe psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophreniaHarv Rev Psychiatry2013211184023656760
   PubMed Web of Science ®Google Scholar
• KaneJMImproving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring successJ Clin Psychiatry2013749e1824107769
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• WeidenPJKimEBermakJTurkozIGopalSBerwaertsJDoes half-life matter after antipsychotic discontinuation? a relapse comparison in schizophrenia with 3 different formulations of paliperidoneJ Clin Psychiatry2017787e813e82028640988
   PubMed Web of Science ®Google Scholar
• MertDGTurgutNHKelleciMSemizMPerspectives on reasons of medication nonadherence in psychiatric patientsPatient Prefer Adherence20159879325609930
   PubMed Web of Science ®Google Scholar
• ValensteinMBlowFCCopelandLAPoor antipsychotic adherence among patients with schizophrenia: medication and patient factorsSchizophr Bull200430225526415279044
   PubMed Web of Science ®Google Scholar
• VelliganDIWeidenPJSajatovicMThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry200970Suppl 4146 quiz 47–4819686636
   PubMed Web of Science ®Google Scholar
• KeithSJPaniLNickBPractical application of pharmacotherapy with long-acting risperidone for patients with schizophreniaPsychiatr Serv2004559997100515345759
   PubMed Web of Science ®Google Scholar
• ChongHYTeohSLWuDBKotirumSChiouCFChaiyakunaprukNGlobal economic burden of schizophrenia: a systematic reviewNeuropsychiatr Dis Treat20161235737326937191
   PubMed Web of Science ®Google Scholar
• DesaiPRLawsonKABarnerJCRascatiKLIdentifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patientsJ Manag Care Pharm201319646847723806061
   PubMed Web of Science ®Google Scholar
• GopalSVermeulenANandyPPractical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaCurr Med Res Opin201531112043205426306819
   PubMed Web of Science ®Google Scholar
• MedicGHigashiKLittlewoodKJDiezTGranströmOKahnRSDosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysisNeuropsychiatr Dis Treat2013911913123355782
   PubMed Web of Science ®Google Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesAm J Manag Care2009156e22e3319514806
   PubMed Web of Science ®Google Scholar
• DaghistaniNReyJAInvega Trinza: The first four-times-a-year, long-acting injectable antipsychotic agentP T201641422222727069340
   PubMedGoogle Scholar
• PilonDJoshiKTandonNTreatment patterns in medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychoticPatient Prefer Adherence20171161962928356723
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUNon-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry201312321622624096780
   PubMed Web of Science ®Google Scholar
• CorrellCUCitromeLHaddadPMThe use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidenceJ Clin Psychiatry201677suppl 312427732772
   PubMed Web of Science ®Google Scholar
• MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital dischargeJ Manag Care Spec Pharm201521975476926308223
   PubMed Web of Science ®Google Scholar
• OstuzziGPapolaDGastaldonCBarbuiCNew EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence baseEpidemiol Psychiatr Sci201726323123328004623
   PubMed Web of Science ®Google Scholar
• LambYNKeatingGMPaliperidone palmitate intramuscular 3-monthly formulation: a review in schizophreniaDrugs201676161559156627699643
   PubMed Web of Science ®Google Scholar
• Invega Trinza^® (paliperidone palmitate) extended-release injectable suspension for intramuscular use: US [prescribing information]Titusville, NJJanssen Pharmaceuticals Inc.2015
   Google Scholar
• ÖzdemirAKPakŞCCananFGeçiciÖKuloğluMGücerMKPaliperidone palmitate use in pregnancy in a woman with schizophreniaArch Womens Ment Health201518573974025599999
   PubMed Web of Science ®Google Scholar
• Zamora RodríguezFJBenítez VegaCSánchez-Waisen HernándezMRGuisado MacíasJAVaz LealFJUse of paliperidone palmitate throughout a schizoaffective disorder patient’s gestation periodPharmacopsychiatry2017501384027414740
   PubMed Web of Science ®Google Scholar
• IlettKFHackettLPKristensenJHVaddadiKSGardinerSJBeggEJTransfer of risperidone and 9-hydroxyrisperidone into human milkAnn Pharmacother200438227327614742766
   PubMed Web of Science ®Google Scholar
• JohnsonJUSFDA approves Invega Trinza first and only four-timesa-year treatment for schizophrenia2015 Available from: https://www.jnj.com/media-center/press-releases/us-fda-approves-invega-trinza-first-and-only-four-times-a-year-treatment-for-schizophreniaAccessed November 06, 2018
   Google Scholar
• BrassoCBellinoSBozzatelloPMontemagniCRoccaPRole of 3-monthly long-acting injectable paliperidone in the maintenance of schizophreniaNeuropsychiatr Dis Treat2017132767277929158676
   PubMed Web of Science ®Google Scholar
• BerwaertsJLiuYGopalSEfficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trialJAMA Psychiatry201572883083925820612
   PubMed Web of Science ®Google Scholar
• RavenstijnPRemmerieBSavitzAPharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyJ Clin Pharmacol201656333033926189570
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSNuamahIHoughDMathewsMPaliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyInt Clin Psychopharmacol201732632933628806194
   PubMed Web of Science ®Google Scholar
• ChirilaCNuamahIWoodruffKHealth care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trialsCurr Med Res Opin20173361083109028277864
   PubMed Web of Science ®Google Scholar
• GopalSXuHMcQuarrieKCaregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studiesNPJ Schizophr2017312328751663
   PubMed Web of Science ®Google Scholar
• JoshiKLafeuilleMHBrownBBaseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world settingCurr Med Res Opin201733101763177228741387
   PubMed Web of Science ®Google Scholar
• KatzEGHauberBGopalSPhysician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trialsPatient Prefer Adherence2016102127213927799749
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority studyInt J Neuropsychopharmacol2016197pyw01826902950
   PubMed Web of Science ®Google Scholar
• UtrechtUEuropean Long-acting Antipsychotics in Schizophrenia Trial (EULAST) Available from: https://clinicaltrials.gov/ct2/show/NCT02146547Accessed November 06, 2018
   Google Scholar
• Janssen Scientific Affairs LA study to compare disease progression and modification following treatment with paliperidone palmitate long-acting injection or oral antipsychotics in participant’s with recent-onset schizophrenia or schizophreniform (DREaM)2018 Available from: https://clinicaltrials.gov/ct2/show/NCT02431702Accessed November 06, 2018
   Google Scholar
• Janssen Research & Development, LLCA Study of Paliperidone Palmitate 6-Month Formulation2018 Available from: https://clinicaltrials.gov/ct2/show/NCT03345342Accessed November 06, 2018
   Google Scholar
• Red Book OnlineTruven Health Analytics Available from: https://truvenhealth.com/Training/Product/IBM-Micromedex-Clinical-Knowledge/IBM-Micromedex-RED-BOOKAccessed November 1, 2017
   Google Scholar
• EinarsonTRBerezaBGTedouriFvan ImpeKDeneeTRDriesPJTCost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the NetherlandsJ Med Econ201720111187119928762843
   PubMed Web of Science ®Google Scholar
• EinarsonTRBerezaBGLlinaresGIGonzalez Martin MoroBTedouriFVan ImpeKCost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in SpainJ Med Econ201720101039104728678566
   PubMed Web of Science ®Google Scholar